Intuitive Surgical reported solid Q2 results, beating revenue and earnings estimates with a 20% increase in da Vinci procedures and a gross margin of 70%. Despite recent market challenges, the company's valuation is near a 5-year low at about 35 times forward earnings, presenting an attractive buying opportunity. The analyst maintains a Buy rating, citing strong long-term growth prospects driven by secular trends, international expansion, and ongoing R&D investments that support high-teens growth and competitive advantages.
Intuitive Surgical's stock has fallen nearly 30%, but the company remains a buy due to resilient adoption metrics and strong growth in system placements and installed base. Despite softer U.S. procedure growth, profitability improved with Q2 non-GAAP...
Several key stocks fell significantly due to company-specific issues. Intuitive Surgical's shares dropped 14.15% despite strong earnings because of slower growth in surgical procedures, impacting related leveraged ETFs. REGENXBIO's stock fell 11.7% a...
Intuitive Surgical reported strong Q2 earnings with adjusted EPS of $2.80, surpassing analyst expectations due to high demand for its da Vinci robotic surgical systems. Despite the positive results, the stock dropped 12% in premarket trading after th...
Intuitive Surgical reported Q2 revenue of $2.89 billion and adjusted earnings of $2.80 per share, beating analyst estimates. However, shares fell 11% as US procedure growth slowed to 12% from 14% in Q1, attributed to deferred treatments and changes i...
Intuitive Surgical reported strong Q2 2026 results, with EPS of $2.80 beating estimates by nearly 13% and revenue reaching $2.89 billion, surpassing forecasts. This marks the fourth consecutive quarter the company has exceeded earnings expectations, ...
